A further decrease in CYB5D2 expression was demonstrated in aggressive versus less aggressive BC sub-types: ER- versus ER+, PR- versus PR+, and HER2+or TN versus ER+in 2 large BC cohorts, the TCGA34 and Curtis datasets6 (Fig. 1E,F). Here, CYB5D2 is linked to breast cancer.